Company / Capital Expenditures
Zenas BioPharma, Inc. Capital Expenditures History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$18.0K
FY2025
5-year range
$17.0K / $18.0K
FY2023-FY2025
Trend
+5.9%
vs FY2024
Sector context
#186 of 194
Health Care
What the data says
Among 194 Health Care companies, Zenas BioPharma, Inc. is in the bottom 4% for capital expenditures. Capital Expenditures remained relatively stable over the past 3 years, with values between $17,000 and $18,000.
Based on SEC 10-K filings.
$18,000 in FY2025.
Improved from $17,000 to $18,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 194This company $18.0K Sector average $117.5M
▼
-100.0% below sector average
Key checks
Key Insights
- In FY2025, capital expenditures increased 5.9% year-over-year.
- Ranks #186 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.0K | +5.9% |
| FY2024 | $17.0K | +0.0% |
| FY2023 | $17.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026